
Relative *Cat* Activity
1
10
100
1000
10000
100000
1000000
Ctr +
Ctr -
G2
G4
G16
Cells

FIG. 1

FIG. 2A

a



FIG. 2B

b





FIG. 2C


293 MOI=2
Infectious Units/Cell
10000
1000
100
10
1
0
1
2
3
4
5
Days

FIG. 3A


293/GV16 MOI=2
Infectious Units/Cell
10000
1000
100
10
1
0
1
2
3
4
5
Days

FIG. 3B


H1299 MOI =10
Total Infectious Units (Log10)
8
7
6
5
4
3
2
1
0
0
24
48
72
96
Hours

FIG. 3C


H1299 MOI=100
Total Infectious Units (Log10)
9
8
7
6
5
4
3
2
0
24
48
72
96
Hours

FIG. 3D


Ad/RSV-hFIX
AdE4A/RSV-hFIX
AdE4B/RSV-hFIX
2h
48h
96h
0 10 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100
2.8kb

FIG. 4


293/GV16
H1299
0
W2
A2
B2
0
W10
A10
B10
W100
A100
B100
E4
Fiber
Actin

FIG. 5


Expression Cassette
Adenoviral Vectors
GT-Luc
PO-Luc
RSV-Luc
PGK-GV16
GT-LacZ

FIG. 6


H1299
Relative Luciferase Units
10⁸
10⁷
10⁶
10⁵
10⁴
10³
10²
10
1
LacZ
RSV-Luc
GT-Luc
PO-Luc
treatment

FIG. 7A


A549
10⁸
10⁷
10⁶
10⁵
10⁴
10³
10²
10
1
LacZ
RSV-Luc
GT-Luc
PO-Luc
treatment

FIG. 7B

Fig. 8A



Fig. 8B



Fig. 8C

Fig. 8D

Treatment

Fig. 8E

Fig. 8F

Fig. 8G

Fig. 8H




G4 BG WT G4 BG WT G4 BG WT AD CK
E4
MOI
10
E4
MOI
~80
1 2 3 4 5 6 7 8 9 10 11
Day 1
Day 3
Day 7

Fig. 9A


Arbitrary Band Intensity
3000
2500
2000
1500
1000
500
0
CK
BG
WT
G4
1
3
7
Days Postinfection

Fig. 9B



Fig. 10A

Fig. 10B

Fig. 10C



BEST AVAILABLE COPY



Fig. 11A

Fig. 11B



Fig. 11C

Fig. 12A



Fig. 12C





Fig. 12B



Fig. 12D

SGOT or SGPT Activity (IU/L)

Days Postinjection



FIG. 13A - FIG. 13F



Fig. 14A

Fig. 14B